Monica Morrow
Overview
Explore the profile of Monica Morrow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
525
Citations
14537
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Han R, Brogi E, Thompson D, El-Tamer M, Morrow M, Wen H
Breast Cancer Res Treat
. 2025 Mar;
PMID: 40025384
Purpose: RxPONDER showed that in postmenopausal women with early-stage hormone receptor + /HER2- breast cancer (BC) with 1-3 positive axillary lymph nodes (LN) and a recurrence score ≤ 25, the...
2.
Perry L, Sevilimedu V, Polidorio N, Abuhadra N, Morrow M, Plitas G, et al.
Ann Surg Oncol
. 2025 Mar;
PMID: 40025324
Background: The combination of pembrolizumab with neoadjuvant chemotherapy (NAC) for triple-negative breast cancer (TNBC) improves pathologic complete response (pCR) rates and event-free survival. Yet it is unclear which patients benefit...
3.
Tadros A, Diskin B, Sevilimedu V, Xu A, Vingan P, Nelson J, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2454506.
PMID: 40009385
Importance: Inflammatory breast cancer (IBC) is an aggressive variant for which trimodality treatment (ie, neoadjuvant systemic therapy [NST] followed by modified radical mastectomy without immediate reconstruction and postmastectomy radiotherapy [PMRT])...
4.
Roberts A, Campbell A, Pollack B, Montagna G, Sevilimedu V, Axelrod B, et al.
Ann Surg Oncol
. 2025 Feb;
PMID: 39971857
Background: Chronic inflammatory responses initiated by lymphatic injury play a key role in the pathophysiology of secondary lymphedema; however, it is unknown if these responses vary by race/ethnicity. We assessed...
5.
Moshe N, Haisraely O, Globus O, Faermann R, Abu-Shehada N, Anaby D, et al.
Radiother Oncol
. 2025 Jan;
205:110710.
PMID: 39862923
Methods: The study was approved by the institutional ethics committee. Data collected included patient- (e.g., age), tumour- (e.g., subtype, stage), and treatment-related factors and outcomes. LR was defined as ipsilateral...
6.
7.
8.
Montagna G, Laws A, Ferrucci M, Mrdutt M, Sun S, Bademler S, et al.
J Clin Oncol
. 2024 Nov;
43(7):810-820.
PMID: 39509672
Purpose: The nodal burden of patients with residual isolated tumor cells (ITCs) in the sentinel lymph nodes (SLNs) after neoadjuvant chemotherapy (NAC) (ypN0i+) is unknown, and axillary management is not...
9.
Matar-Ujvary R, Sevilimedu V, Morrow M
Ann Surg Oncol
. 2024 Nov;
32(1):125-126.
PMID: 39500860
No abstract available.
10.
Yang E, DAlfonso T, Morrow M, Brogi E, Wen H
Histopathology
. 2024 Oct;
86(3):441-449.
PMID: 39420445
Aims: Breast cancer with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 1+ or 2+ with negative in-situ hybridisation (ISH) (HER2-low) can now be targeted by HER2 antibody drug...